文献速递其他结缔组织病

多发性肌炎/皮肌炎相关间质性肺病患者治疗前死亡风险预测模型

Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease.
PubMed 文献 · RMD Open · 2024-04-24

本研究基于南京鼓楼医院2016至2021年收治的418例多发性肌炎/皮肌炎相关间质性肺病(PM/DM-ILD)患者,开发并验证了一个治疗前死亡风险预测模型。模型整合年龄、关节痛、抗MDA5抗体状态、高分辨率CT模式及由C反应蛋白、乳酸脱氢酶、CD3+CD4+ T细胞计数和PO2/FiO2构成的实验室风险评分,在开发队列中表现出良好的区分度(AUC 0.869,95%CI 0.811至0.910)、校准度和临床实用性,并可将患者分为三个死亡风险不同的组别。

要点

  • 模型纳入年龄、关节痛、抗MDA5抗体、HRCT模式及4项实验室指标构成的评分。
  • 开发队列AUC为0.869(95%CI 0.811至0.910),校准良好且临床实用。
  • 患者按模型分为三个风险组,各组死亡率不同。

核心结论

  • 开发并验证了一个基于简单易得临床变量的循证死亡风险预测模型,可能有助于临床决策。

研究设计与样本

  • 预后研究,分析南京鼓楼医院2016至2021年收治的PM/DM-ILD患者。
  • 共纳入418例患者,随机分为开发队列(n=282)和验证队列(n=136)。
  • 主要结局为1年内死亡。
  • 采用LASSO logistic回归识别预测性实验室指标并构建实验室风险评分,结合临床因素建立死亡风险预测模型。
  • 模型评估涵盖区分度、校准度、临床效用及风险预测与预后实际应用。

主要发现

  • LASSO logistic回归在开发队列中识别出4个最优特征构成实验室风险评分:C反应蛋白、乳酸脱氢酶、CD3+CD4+ T细胞计数和PO2/FiO2。
  • 最终预测模型整合年龄、关节痛、抗黑色素瘤分化相关基因5抗体状态、高分辨率CT模式及实验室风险评分。
  • 预测模型表现出稳健的区分度(受试者工作特征曲线下面积:0.869,95%CI 0.811至0.910)、出色的校准度和有价值的临床效用。
  • 患者被分为三个风险组,各组死亡率不同。
  • 内部验证、敏感性分析及与既往模型的比较评估进一步证实了预测模型的稳健性。

关键数值与推荐

  • 实验室风险评分包含C反应蛋白、乳酸脱氢酶、CD3+CD4+ T细胞计数和PO2/FiO2四项指标。
  • 最终预测模型纳入年龄、关节痛、抗MDA5抗体状态、高分辨率CT模式和实验室风险评分。
  • 模型区分度:AUC 0.869(95%CI 0.811至0.910)。
  • 患者分为三个风险组,各组死亡率不同(原文未报告具体死亡率数值)。

临床怎么用

  • 原文结论指出该模型可能有助于临床决策,未给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Risk prediction for patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD) is challenging due to heterogeneity in the disease course. We aimed to develop a mortality risk prediction model for PM/DM-ILD. METHODS: This prognostic study analysed patients with PM/DM-ILD admitted to Nanjing Drum Hospital from 2016 to 2021. The primary outcome was mortality within 1 year. We used a least absolute shrinkage and selection operator (LASSO) logistic regression model to identify predictive laboratory indicators. These indicators were used to create a laboratory risk score, and we developed a mortality risk prediction model by incorporating clinical factors. The evaluation of model performance encompassed discrimination, calibration, clinical utility and practical application for risk prediction and prognosis. RESULTS: Overall, 418 patients with PM/DM-ILD were enrolled and randomly divided into development (n=282) and validation (n=136) cohorts. LASSO logistic regression identified four optimal features in the development cohort, forming a laboratory risk score: C reactive protein, lactate dehydrogenase, CD3+CD4+ T cell counts and PO2/FiO2. The final prediction model integrated age, arthralgia, anti-melanoma differentiation-associated gene 5 antibody status, high-resolution CT pattern and the laboratory risk score. The prediction model exhibited robust discrimination (area under the receiver operating characteristic: 0.869, 95% CI 0.811 to 0.910), excellent calibration and valuable clinical utility. Patients were categorised into three risk groups with distinct mortality rates. The internal validation, sensitivity analyses and comparative assessments against previous models further confirmed the robustness of the prediction model. CONCLUSIONS: We developed and validated an evidence-based mortality risk prediction model with simple, readily accessible clinical variables in patients with PM/DM-ILD, which may inform clinical decision-making.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Gui X, Li W, Jiang H, et al. Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease. RMD Open. 2024. PMID: 38663883. doi:10.1136/rmdopen-2023-003850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。